ライフサイエンスコーパス: second-line treatment

1 -related mortality still restrict its use to second line treatment.

2 sent a reliable tool for predicting OS after second-line treatment.

3 % are refractory to medical therapy and seek second-line treatment.

4 FFS was 56% at 6 months after second-line treatment.

5 e mortality, and recurrent malignancy during second-line treatment.

6 he second year of ART to guide the switch to second-line treatment.

7 even after adjusting for RFI and response to second-line treatment.

8 to paclitaxel had failed to respond to their second-line treatment.

9 ast cancer, and the other 25% received it as second-line treatment.

10 the risk conferred by maternal T2D requiring second-line treatment.

11 nd in proton pump inhibitors (PPIs) doses in second-line treatment.

12 cillin and adverse events both in first- and second-line treatment.

13 nferior efficacy of cladribine in first- and second-line treatment.

14 sitive PD-L1 staining, received nivolumab as second-line treatment.

15 0 copies per mL) at 12 months after starting second-line treatment.

16 nus kinase 2 (JAK2) inhibitor ruxolitinib is second-line treatment.

17 -thirds of patients with aUC did not receive second-line treatment.

18 -line but many patients die before receiving second-line treatment.

19 and can be considered a suitable option for second-line treatment.

20 th HIV taking DTG with food as part of their second-line treatment.

21 of 289 patients died without progressing to second-line treatment.

22 med RR-TB and those reported to have started second-line treatment.

23 l cancer who may benefit from gefitinib as a second-line treatment.

24 e treatment and rituximab-based regimens for second-line treatment.

25 order of hormonal therapies for CRPC beyond second-line treatment.

26 reduced sensitivity, and foregone savings in second-line treatment.

27 6 Italian centers, were submitted to ECP for second-line treatment.

28 ternative that is often, but not always, the second-line treatment.

29 ontrolled, phase 3 studies of first-line and second-line treatment.

30 ssion-free survival (PFS) following first or second-line treatment.

31 enefits for trastuzumab emtansine (T-DM1) in second-line treatment.

32 onal outcomes with clozapine positioned as a second-line treatment.

33 rognosis is better than in those who require second-line treatments.

34 ce observed among the current first-line and second-line treatments.

35 istance to 16 TB drugs, including first- and second-line treatments.

36 angitis (PBC) has changed with the advent of second-line treatments.

37 matically analyze the response to first- and second-line treatments.

38 outcome after ESA failure and the effect of second-line treatments.

39 al patients responded variably to first- and second-line treatments.

40 rding which patients will benefit from which second-line treatments.

41 is inadequately treated with first-line and second-line treatments.

42 Of 450 patients (39%) who received second-line treatment, 194 received HMAs, 148 received L

43 choice between rituximab and splenectomy in second-line treatment, (3) the need of periodical re-eva

44 Overall, 75 (54%) of patients received second-line treatment, 33/75 (44%) correlate-guided.

45 For second-line treatment, a novel alkylating agent, lurbine

46 ulation (excluding those who did not require second-line treatment after randomisation and those who

47 are potential predictive biomarkers to guide second-line treatments after HMA failure.

48 stance can lead to long-term cost savings in second-line treatment and (ii) its higher sensitivity co

49 After exclusion of those who did not require second-line treatment and those who did not consent, 286

50 or metastatic urothelial carcinoma receiving second-line treatment and warrants further investigation

51 ese, only 2714 (37.4%) progressed to receive second-line treatment, and 857 (11.8%) advanced to third

52 ines are first-line treatment, omalizumab is second-line treatment, and cyclosporine is third-line tr

53 servation of ritonavir-boosted lopinavir for second-line treatment, and harmonization of adult and pe

54 group, PFS for first-line treatment, PFS for second-line treatment, and patient-reported quality of l

55 ation, lower gastrointestinal involvement at second-line treatment, and severe NIH global score at se

56 proved in the US since 2017 as adjunctive or second-line treatments, and hematopoietic stem cell tran

57 hlorambucil, or alemtuzumab as first-line or second-line treatment; and had an Eastern Cooperative On

58 g the use of mycophenolate and tacrolimus as second-line treatment; and the recent completion of the

59 Methotrexate, which is recommended as a second-line treatment, appears to have fewer side effect

60 ine treatment and trastuzumab deruxtecan for second-line treatment are recommended.

61 axane for first-line treatment and T-DM1 for second-line treatment are recommended.

62 However, prognosis and effects of second-line treatment are thus far unknown.

63 Responses to second-line treatment are uncommon.

64 Babies who require second-line treatments are more likely to have hypoxic i

65 than 30x10(9) per liter and initiation of a second-line treatment, assessed in a time-to-event analy

66 se agents are not recommended as a first- or second-line treatment at this time.

67 and Titrated for Irritable Bowel Syndrome as Second-Line Treatment [ATLANTIS]) was conducted at 55 ge

68 ntrahepatic portosystemic shunts (TIPS) is a second-line treatment because of an increased incidence

69 ering low- dose tricyclic antidepressants as second-line treatment, but their effectiveness in primar

70 Second-line treatments can improve survival and quality

71 togen underwent fewer surgical procedures or second line treatments compared with those randomised to

72 t, the notable reduction in response rate to second-line treatments, coupled with clozapine's substan

73 HIV-1 infection who were starting first- or second-line treatment, dolutegravir-based ART was superi

74 Few effective second-line treatments exist for women with recurrent or

75 ore effective than either alone and provides second line treatment for those with rhinitis poorly con

76 al photopheresis (ECP) is considered a valid second-line treatment for acute and chronic graft versus

77 ould become standard-of-care chemotherapy in second-line treatment for advanced biliary tract cancer

78 Systemic therapy is generally recommended as second-line treatment for advanced HCC in the major guid

79 oint blockers have recently been approved as second-line treatment for advanced non-small-cell lung c

80 e monoclonal anti-IgE antibody omalizumab as second-line treatment for antihistamine-refractory chron

81 renewed enthusiasm for the use of niacin as second-line treatment for atherogenic dyslipidemia, with

82 eurin inhibitors (TCIs) are commonly used as second-line treatment for atopic dermatitis.

83 tinuous positive airway pressure is a useful second-line treatment for children with sleep-disordered

84 ated with endocrine therapy as first-line or second-line treatment for hormone receptor-positive, HER

85 e amitriptyline was superior to placebo as a second-line treatment for IBS in primary care across mul

86 -FU, and folinic acid may represent the best second-line treatment for improved survival outcomes in

87 egravir dispersible tablets as first-line or second-line treatment for infants and children aged less

88 s-sectional study examines atezolizumab as a second-line treatment for malignant urothelial carcinoma

89 d favorable efficacy and tolerability in the second-line treatment for metastatic esophagogastric ade

90 (177)Lu-DOTATATE is an effective second-line treatment for metastatic or nonresectable ne

91 y and safety of axitinib versus sorafenib as second-line treatment for metastatic renal cell carcinom

92 nib is an oral angiokinase inhibitor used as second-line treatment for non-small cell lung cancer.

93 tment for BRAF and NRAS mutant melanomas and second-line treatment for patients who develop resistanc

94 xel, and could be regarded as a new standard second-line treatment for patients with advanced gastric

95 emiplimab at progression might provide a new second-line treatment for patients with advanced non-sma

96 versible EGFR tyrosine kinase inhibitor), as second-line treatment for patients with advanced squamou

97 the official approval of obeticholic acid as second-line treatment for patients with an incomplete re

98 median follow-up of 47.2 months, axi-cel as second-line treatment for patients with early relapsed o

99 ne therapy; biologics such as adalimumab are second-line treatment for patients with inflammation ref

100 rvival compared with placebo plus FOLFIRI as second-line treatment for patients with metastatic color

101 plus paclitaxel versus gemcitabine alone as second-line treatment for patients with metastatic pancr

102 cetaxel can be recommended as an appropriate second-line treatment for patients with oesophagogastric

103 nation with paclitaxel could be an effective second-line treatment for patients with platinum-pretrea

104 US Food and Drug Administration in 2016 as a second-line treatment for patients with primary biliary

105 and it is now considered standard of care as second-line treatment for patients with recurrent/refrac

106 ith docetaxel plus ramucirumab or placebo as second-line treatment for patients with stage IV non-sma

107 al impact and cost-effectiveness of OCA as a second-line treatment for PBC in combination with ursode

108 considered the staple therapy for gout and a second-line treatment for pericarditis, as well as a bas

109 lysis of liso-cel versus standard of care as second-line treatment for primary refractory or early re

110 ment initiation and loss to follow-up before second-line treatment for RR-TB across South Africa.

111 nd efficacy of amrubicin versus topotecan as second-line treatment for SCLC.

112 1 phototherapy may be considered a potential second-line treatment for VLS.

113 Identification of more effective second-line treatments for advanced relapsing and refrac

114 that ruxolitinib is not superior to current second-line treatments for ET.

115 Patients who received rituximab as second-line treatment had shorter DFS than patients trea

116 chimeric antigen receptor T-cell therapy, as second-line treatment had significantly longer event-fre

117 unknown primary site (CUP), and no effective second-line treatment has been identified.

118 As a second-line treatment, he received Nivolumab therapy wit

119 ed with ESAs, none of the most commonly used second-line treatments (HMA and LEN) significantly impro

120 atients are offered URD transplantation as a second-line treatment; however, the impact of pretranspl

121 rognostic factor for treatment failure after second-line treatment (HR, 1.2 per 10 years; 95% CI, 1.2

122 ecomes more common, especially as first- and second-line treatments, immunotoxicity and autoimmunity

123 rol and Prevention recommended cefixime as a second-line treatment in 2021.

124 rformed as first-line treatment in 25.4%, as second-line treatment in 38.4%, and as salvage treatment

125 gated the activity of abiraterone acetate as second-line treatment in ADT-resistant, AR+ patients wit

126 ic antigen receptor (CAR) T-cell product, as second-line treatment in adults with relapsed or refract

127 rapy as a potential new standard of care for second-line treatment in appropriate patients with refra

128 l photopheresis is confirmed as an effective second-line treatment in both aGVHD and cGVHD, because i

129 Second-line treatment in castration-resistant patients i

130 d pulmonary MDR tuberculosis at the start of second-line treatment in Estonia, Latvia, Peru, Philippi

131 trials have investigated their efficacy as a second-line treatment in high-risk relapsed or refractor

132 -receptor agonists (TPO-RAs) is an effective second-line treatment in immune thrombocytopenia (ITP).

133 The use of gefitinib as a second-line treatment in oesophageal cancer in unselecte

134 Regarding second-line treatment in patients who received first-lin

135 port lisocabtagene maraleucel as a potential second-line treatment in patients with large B-cell lymp

136 vatinib, everolimus, or their combination as second-line treatment in patients with metastatic renal

137 to peptide receptor radionuclide therapy as second-line treatment in patients with progressive liver

138 ty of afatinib compared with methotrexate as second-line treatment in patients with recurrent or meta

139 compared with an ORR of 15% for topotecan as second-line treatment in patients with SCLC sensitive to

140 and titrated for irritable bowel syndrome as second-line treatment in primary care (ATLANTIS): a rand

141 d antitumor response than PD-L1 alone as the second-line treatment in SCLC.

142 onavir-boosted lopinavir (LPV/r) regimen for second-line treatment in South Africa.

143 in the mPC cohort (1502 [43.0%]) and before second-line treatment in the aUC cohort.

144 b treatment, further supporting its use as a second-line treatment in these patients.

145 irst-line treatment in cold-type AIHA and as second-line treatment in warm-type AIHA and patients wit

146 ive analysis of early response to first- and second-line treatments in 127 patients with classic HL w

147 lusion: The findings support that first- and second-line treatments in HL do not require different re

148 ines Agency-should be preferentially used as second-line treatments in these patient populations, typ

149 mphoma are cured with various first-line and second-line treatments, including ABVD, BEACOPP, and ste

150 Second-line treatments, including hypomethylating agents

151 pective cohort study was conducted to assess second-line treatment initiation and treatment delay amo

152 bout the functional relationship of delaying second-line treatment initiation for human immunodeficie

153 o 5 controls by birth year, sex, and date of second-line treatment initiation.

154 posure of DTG taken with food in children on second-line treatment is comparable with that of childre

155 with steroid-refractory disease, response to second-line treatment is dismal.

156 ivation rates remain above 30%, and standard second-line treatment is yet to be established.

157 Access to recommended second-line treatments is limited for patients who fail

158 de, and rituximab regimen in both first- and second-line treatments (median VAF increase, 14.8x and 1

159 Radiotherapy can be used as a second-line treatment modality.

160 For second-line treatment, nivolumab plus ipilimumab could b

161 FFS was defined by the absence of second-line treatment, nonrelapse mortality, and recurre

162 ar on ART, whereas higher rates of switch to second-line treatment occurred in LCM from the second ye

163 CPT analogue that was recently approved for second line treatment of colorectal cancer, the 20(S)-gl

164 formulation of an established agent for the second-line treatment of advanced epithelial ovarian can

165 abozantinib with best supportive care in the second-line treatment of advanced hepatocellular carcino

166 Second-line treatment of advanced NSCLC with pemetrexed

167 There is no consensus for selection of second-line treatment of chronic EM.

168 placement of splenectomy with rituximab as a second-line treatment of chronic immune thrombocytopenic

169 atin, and etoposide (BV-ICE) chemotherapy in second-line treatment of classical Hodgkin lymphoma.

170 igen receptor (CAR) T-cell therapies for the second-line treatment of high-risk large B-cell lymphoma

171 alone might be appropriate for first-line or second-line treatment of hormone receptor-positive, HER2

172 rent endocrine therapy partners as first- or second-line treatment of hormone receptor-positive/human

173 reverse-transcriptase inhibitors (NRTIs) for second-line treatment of human immunodeficiency virus ty

174 Although initially restricted to the second-line treatment of ITP, both agents could help tre

175 d irinotecan (FOLFIRI) + bevacizumab for the second-line treatment of KRAS-mutant metastatic colorect

176 commercial CD19-directed CAR T cells in the second-line treatment of LBCL, addressing crucial questi

177 Few treatment options exist for second-line treatment of malignant pleural mesothelioma.

178 rinotecan with or without bevacizumab in the second-line treatment of metastatic colorectal cancer.

179 ecan/docetaxel and irinotecan/gemcitabine in second-line treatment of non-small-cell lung cancer (NSC

180 can and gemcitabine, with or without CBX, in second-line treatment of NSCLC.

181 Most phase I and II data came from second-line treatment of ovarian cancer, and there have

182 side effects compared with docetaxel in the second-line treatment of patients with advanced NSCLC an

183 ingle-agent pemetrexed is safe and active as second-line treatment of patients with advanced TCC of t

184 s active and well tolerated in the first- or second-line treatment of patients with advanced transiti

185 added to systemic therapy in the first- and second-line treatment of patients with colorectal liver

186 d, for several decades, there was no optimal second-line treatment of patients with corticosteroid-re

187 only used chemotherapies improved PFS in the second-line treatment of patients with HER2-negative met

188 tion with endocrine therapy as first-line or second-line treatment of patients with hormone receptor-

189 herapy regimens versus chemotherapy alone as second-line treatment of patients with human epidermal g

190 vacizumab showed significant activity in the second-line treatment of patients with KRAS-mutant mCRC,

191 survival when compared with topotecan in the second-line treatment of patients with SCLC.

192 ce exists to support the use of nivolumab as second-line treatment of patients with squamous advanced

193 ucirumab plus docetaxel improves survival as second-line treatment of patients with stage IV NSCLC.

194 a benchmark for future trials investigating second-line treatment of PDAC.

195 pport the use of CPI therapies for first- or second-line treatment of recurrent or metastatic HNSCC.

196 r PLD alone with acceptable tolerance in the second-line treatment of recurrent ovarian cancer.

197 se of Sulphadoxine-pyrimethamine (SP) as the second-line treatment of uncomplicated falciparum malari

198 have greater efficacy than paclitaxel in the second-line treatment of urothelial cancers.

199 on (AF) has emerged as a widespread first or second line treatment option.

200 ginterferon alfa-2b could be considered as a second-line treatment option for patients with essential

201 These results establish axitinib as a second-line treatment option for patients with metastati

202 antitumour activity and is a first-line and second-line treatment option for patients with programme

203 arcinoma, and might represent a new standard second-line treatment option for these patients.

204 A second-line treatment option is azathioprine, but effica

205 is no definitive consensus on the preferred second-line treatment option.

206 Few standard second-line treatment options exist for advanced sarcoma

207 ng randomized controlled trial investigating second-line treatment options for children with HIV.

208 Doubts exist regarding optimal second-line treatment options for HIV-1-infected patient

209 udied and several advances in first-line and second-line treatment options should yield significant i

210 (mBCC) is a rare condition with no effective second-line treatment options.

211 g a dismal prognosis due to lack of approved second-line treatment options.

212 shed, traditional therapies as first-line or second-line treatment options.

213 ocarcinoma have a poor prognosis and limited second-line treatment options.

214 Because first-line or second-line treatments, or both, based on chemotherapy a

215 without targeted therapies as first-line or second-line treatments, or both, in postmenopausal women

216 ies plus targeted therapies as first-line or second-line treatments, or in both settings, in women wi

217 time from splenectomy to the initiation of a second-line treatment (other than steroids and intraveno

218 e intervals between last treatment cycle and second-line treatment point towards clinical progression

219 r effective drug combinations for first- and second-line treatments, post-exposure prophylaxis, and t

220 These results support liso-cel as a new second-line treatment recommendation in patients with ea

221 elapsed or refractory osteosarcoma; however, second-line treatment recommendations vary across guidel

222 R-TB receiving an all oral bedaquiline-based second-line treatment regimen displayed a similar microb

223 in the post-implementation group initiated a second-line treatment regimen more rapidly than those in

224 cacy of the currently recommended first- and second-line treatment regimens for this condition is inc

225 n of the market for drugs for first-line and second-line treatment regimens, having supplied, for exa

226 t data on the efficacy and tolerability of 2 second-line treatment regimens.

227 ll consecutive patients who underwent an ITP second-line treatment: Rituximab or splenectomy.

228 an additional option in the postadjuvant or second-line treatment setting for patients who experienc

229 -line therapies, there is an urgent need for second-line treatment strategies for pediatric patients

230 In this comparative effectiveness study of second-line treatment strategies for women with IGE, no

231 ding could have significant implications for second-line treatment strategies in this clinical settin

232 Second-line treatment strategies included intensified sa

233 icosteroids followed by various conventional second-line treatments such as methotrexate and azathiop

234 By combining screening with second-line treatments targeting innate insensitivity, u

235 ves should be used (prescribed) as first- or second-line treatments, though a consensus agreed that b

236 t efficacy.If the first-line therapy fails a second-line treatment using tetracycline, furazolidone a

237 improved OS was associated with response to second-line treatment versus no response (46% v 0%, resp

238 We observed that splenectomy for ITP second-line treatment was more effective than Rituximab

239 The median time on second-line treatment was only 2.1 months with a median

240 Second-line treatment was predefined (FOLFIRI for the EC

241 cin or levofloxacin within triple therapy as second-line treatment were associated with greater effec

242 ne treatment, and severe NIH global score at second-line treatment were associated with increased ris

243 (excluded patients who died without starting second-line treatment) were evaluated.

244 with convulsive status epilepticus requiring second-line treatment, were randomly assigned (1:1) usin

245 ome of 119 patients who received a 2G-TKI as second-line treatment while still in the chronic phase.

246 ffectiveness than bismuth-based therapy as a second-line treatment, while bismuth-based therapy achie

247 Second-line treatment with chemotherapy is generally res

248 patients with metastatic colorectal cancer, second-line treatment with FOLFOX4 is superior to treatm

249 men; 9 [12%] Black; 66 [85%] White) received second-line treatment with gemcitabine plus nab-paclitax

250 Second-line treatment with ramucirumab did not significa

251 Second-line treatment with rituximab leads to response r

252 control duration with avelumab over standard second-line treatment, with a favorable safety profile.

253 ) achieved a partial or complete response to second-line treatment, with a median duration of respons